Synonyms: Dimebolin, Latrepirdine, Pf-01913539
Chemical Name: 3,6-dimethyl-9-(2-methyl-pyridyl-5)-ethyl-1,2,3,4-tetrahydro-γ-carboline dihydrochloride
Therapy Type: Small Molecule
Target Type: Unknown
Condition(s): Alzheimer's Disease
U.S. FDA Status: Alzheimer's Disease (Inactive)
Company: Medivation, Inc.
Approved for: Anti-histamine use in Russia
Dimebon is an antihistamine compound with a long history of clinical use in Russia.
Dimebon has been reported to modulate the activity of a variety of channels and neurotransmitter systems including L-type calcium channels (Lermontova et al., 2001), AMPA and NMDA glutamate receptors (Grigorev et al., 2003), α-adrenergic receptors (α1A, α1B, α1D, and α2A), histamine H1 and H2 receptors and serotonin 5-HT2c, 5-HT5A, 5-HT6 receptors (Wu et al., 2008). Dimebon has also been proposed to exert neuroprotective effects by blocking mitochondrial permeability transition pores (Bachurin et al., 2003)
No Available References
No Available Further Reading